Eliksa Therapeutics
3 known investors
Eliksa develops regenerative medicine therapies for rare diseases, processing acellular biological products in its own cGMP facility. Its lead investigational product, ELK-003, is an ophthalmic eye-drop drug targeting the ocular effects of Epidermolysis Bullosa, an ultra-rare genetic disorder affecting children.
BiotechDigital HealthMedical Devices
Investors Β· 3
Frequently asked questions
- What does Eliksa Therapeutics do?
- Eliksa develops regenerative medicine therapies for rare diseases, processing acellular biological products in its own cGMP facility. Its lead investigational product, ELK-003, is an ophthalmic eye-drop drug targeting the ocular effects of Epidermolysis Bullosa, an ultra-rare genetic disorder affecting children.
- Who are Eliksa Therapeutics's investors?
- Eliksa Therapeutics's investors include Militia Hill Ventures, Ben Franklin Technology Partners, BioAdvance.